Statera Biopharma - Stock Price History | STAB

Historical daily share price chart and data for Statera Biopharma since 2021 adjusted for splits. The latest closing stock price for Statera Biopharma as of October 15, 2021 is 3.22.
  • The all-time high Statera Biopharma stock closing price was 273.60 on September 12, 2007.
  • The Statera Biopharma 52-week high stock price is 10.97, which is 240.7% above the current share price.
  • The Statera Biopharma 52-week low stock price is 2.11, which is 34.5% below the current share price.
  • The average Statera Biopharma stock price for the last 52 weeks is 4.38.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Statera Biopharma Historical Annual Stock Price Data
Year Average Stock Price Year Open Year High Year Low Year Close Annual % Change
2020 2.2527 0.6150 4.2600 0.5702 3.4500 473.09%
2019 1.2750 1.2400 2.0376 0.5138 0.6020 -40.40%
2018 2.5380 3.8600 4.1500 1.0100 1.0100 -74.81%
2017 2.7034 1.4500 5.1000 1.4500 4.0099 182.39%
2016 2.3638 3.3200 3.9000 1.3700 1.4200 -59.31%
2015 3.8027 6.1600 6.2000 1.9300 3.4900 -38.77%
2014 11.1774 23.6000 24.8000 5.3980 5.7000 -75.64%
2013 31.8827 27.0000 43.2000 19.8000 23.4000 -12.03%
2012 41.6293 60.0000 78.0000 24.2000 26.6000 -53.50%
2011 94.2611 141.2000 168.0000 43.8000 57.2000 -60.39%
2010 90.1781 70.0000 145.0000 58.2000 144.4000 118.13%
2009 68.9283 44.9980 121.6000 26.4000 66.2000 55.40%
2008 82.9871 160.4000 160.4000 37.2000 42.6000 -75.80%
2007 195.9887 95.6000 273.6000 91.2000 176.0000 74.60%
2006 100.7032 106.0000 115.0000 87.8000 100.8000 0.00%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.091B $0.000B
Statera BioPharma is a clinical-stage biopharmaceutical company developing novel immunotherapies targeting autoimmune, neutropenia/anemia, emerging viruses and cancers based on a proprietary platform designed to rebalance the body's immune system and restore homeostasis. Statera BioPharma, formerly known as Cytocom Inc., is based in FORT COLLINS, Colo.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $128.216B 8.54
Bio-Rad Laboratories (BIO.B) United States $21.975B 46.83
QIAGEN (QGEN) Netherlands $11.812B 20.00
Biohaven Pharmaceutical Holding (BHVN) United States $8.815B 0.00
Emergent Biosolutions (EBS) United States $2.763B 6.66
Arcus Biosciences (RCUS) United States $2.321B 0.00
Myovant Sciences (MYOV) United Kingdom $1.993B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.769B 0.00
Zymeworks (ZYME) Canada $1.152B 0.00
Ambrx Biopharma (AMAM) United States $0.431B 0.00
SQZ Biotechnologies (SQZ) United States $0.346B 0.00
Enzo Biochem (ENZ) United States $0.188B 18.43